

New Drugs to Be Added to NHI Price List on April 18, 2018

Brand name	Specification	Company	Generic name	NHI price (yen)	Pricing method	Premium, etc.	Indication
Rexulti Tablets 1 mg 2 mg	1 mg/tablet 2 mg/tablet	Otsuka Pharmaceutical	brexpiprazole	268.90 509.20	Similar efficacy comparison method (I)		Schizophrenia (NME)
Atozet Combination Tablets LD HD	1 tablet 1 tablet	MSD	ezetimibe + atorvastatin calcium hydrate	177.00 177.00	Special pricing rule for new combination drugs		Hypercholesterolemia and familial hypercholesterolemia (New combination drug)
Nexium Granules for Suspension 10 mg 20 mg	10 mg/sachet 20 mg/sachet	AZ	esomeprazole magnesium hydrate	80.60 140.30	Similar efficacy comparison method (I)	Premium for pediatric use (5%)	Gastric ulcer, duodenal ulcer, marginal ulcer, reflux esophagitis, non-erosive gastroesophageal reflux disease, and Zollinger-Ellison syndrome (Additional formulation and dosage)
Goofice Tablets 5 mg	5 mg/tablet	EA Pharma	elobixibat hydrate	105.80	Similar efficacy comparison method (I)		Chronic constipation (excluding structural disease-induced constipation) (NME)
Lynparza Tablets 100 mg 150 mg	100 mg/tablet 150 mg/tablet	AZ	olaparib	3,996.00 5,932.50	Cost calculation method	Premium for usefulness (II) (5%) Coefficient: 0.2 (cost disclosure level: <50%)	Maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer (NME)
Cedarcure Japanese Cedar Pollen Sublingual Tablets 2,000 JAU 5,000 JAU	2,000 JAU/tablet 5,000 JAU/tablet	Torii	cedar pollen extract	57.70 144.10	Similar efficacy comparison method (I)	Premium for usefulness (II) (5%) Premium for pediatric use (5%)	Hyposensitization therapy for cedar pollen allergy (NME)
Sirturo Tablets 100 mg	100 mg/tablet	Janssen	bedaquiline fumarate	21,872.50	Similar efficacy comparison method (I)		Multidrug-resistant pulmonary tuberculosis (NME)
Ibulief IV Injection 20 mg	20 mg/2 mL/vial	Senju Pharmaceutical	ibuprofen lysine L-lysine	13,012	Cost calculation method		Patent ductus arteriosus in premature babies in cases not controlled with conservative therapies (such as fluid restriction and diuretics) (NME)
Fasenra SC Injection 30 mg Syringe	30 mg/1 mL/syringe	AZ	benralizumab (recombinant)	351,535	Similar efficacy comparison method (I)		Bronchial asthma (only in refractory patients whose asthma symptoms cannot be controlled with existing treatments) (NME)
Besponsa Injection 1 mg	1 mg/vial	Pfizer	inotuzumab ozogamicin (recombinant)	1,307,092	Cost calculation method	Premium for usefulness (II) (10%) Premium for marketability (I) (10%) Coefficient: 0.2 (cost disclosure level: <50%)	Recurrent or intractable CD22-positive acute lymphoblastic leukemia (NME)
Istodax Injection 10 mg	10 mg/vial (with solvent)	Celgene	romidepsin	109,753	Similar efficacy comparison method (I)		Relapsed or refractory peripheral T-cell lymphoma (NME) Orphan drug
Tecentriq IV Infusion 1,200 mg	1,200 mg/20 mL/vial	Chugai	atezolizumab (recombinant)	625,567	Similar efficacy comparison method (I)		Unresectable, advanced/recurrent non-small cell lung cancer (NME)
Dupilixent SC Injection 300 mg Syringe	300 mg/2 mL/syringe	Sanofi	dupilumab (recombinant)	81,640	Cost calculation method	Premium for usefulness (I) (45%) Coefficient: 0.2 (cost disclosure level: <50%)	Atopic dermatitis inadequately controlled with existing therapies (NME)
Naruvein Injection 2 mg 20 mg	2 mg/1 mL/tube 20 mg/2 mL/tube	Daiichi Sankyo Propharma	hydromorphone HCl	725 6,340	Similar efficacy comparison method (I)		Moderate to severe cancer pain (Additional administration route)
Allesaga Tape 4 mg 8 mg	4 mg/sheet 8 mg/sheet	Hisamitsu	emedastine difumarate	67.50 93.10	Similar efficacy comparison method (I)		Allergic rhinitis (Additional administration route)